Shishodia Shishir, Aggarwal Bharat B
Cytokine Research Section, Department of Bioimmunotherapy, Unit 143, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston 77030, USA.
Biochem Pharmacol. 2004 Sep 15;68(6):1071-80. doi: 10.1016/j.bcp.2004.04.026.
Nuclear transcription factor NF-kappaB, initially discovered as a factor in the nucleus of B cells that binds to the enhancer of the kappa light chain of immunoglobulin, has since been shown to be expressed ubiquitously in the cytoplasm of all cell types, conserved from Drosophila to man. It translocates to the nucleus only when activated, where it regulates the expression of over 200 genes that control the immune system, growth, and inflammation. The dysregulation of NF-kappaB can mediate a wide variety of diseases including cancer. Whether NF-kappaB activation is beneficial or harmful for cancer is controversial. The development of novel therapeutics targeting NF-kappaB requires full understanding of its role in pathology and physiology. The current review is an attempt to describe two sides of the NF-kappaB coin; viz, as a friend and as a foe.
核转录因子NF-κB最初是作为B细胞核内与免疫球蛋白κ轻链增强子结合的一种因子被发现的，后来发现它在所有细胞类型的细胞质中普遍表达，从果蝇到人类都高度保守。它只有在被激活时才会转移到细胞核内，在细胞核中它调控200多个控制免疫系统、生长和炎症的基因的表达。NF-κB的失调可介导包括癌症在内的多种疾病。NF-κB激活对癌症有益还是有害存在争议。开发针对NF-κB的新型疗法需要全面了解其在病理生理学中的作用。本综述旨在描述NF-κB的两面性，即既是朋友又是敌人。
